



**Commercialization Readiness Pilot (CRP) Program
Technical Assistance Now Available**

NCATS

COLLABORATE. INNOVATE. ACCELERATE.

Deadline September 8, 2020 at 5:00 p.m.

The [National Center for Advancing Translational Sciences \(NCATS\)](#) invites Phase II SBIR/STTR grantees to apply to the [Commercialization Readiness Pilot \(CRP\) program](#). This program aims to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts.

- **SBIR/STTR:** [PAR-20-128](#)

NCATS is interested in CRP applications from NCATS Phase II funded applicants, provided they are within the NCATS mission. Applicants are encouraged to contact Scientific/Research staff about anticipated activities prior to submission. Please note that NCATS will not accept applications that include clinical trials, defined as a prospective biomedical or behavioral research study of human subjects designed to answer specific questions about safety, tolerability, efficacy and/or effectiveness of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions.

Additional Funding Opportunities

NCATS has several other targeted funding opportunities

available through the SBIR and STTR programs for entrepreneurs aiming to commercialize innovations in translational science. Standard due dates apply.

PHS 2020 Omnibus Solicitation of the NIH

- SBIR (R43/R44): [PA-20-260](#)
- STTR (R41/R42): [PA-20-265](#)

Non-Viral Technologies for In Vivo Delivery of Genome Editors (clinical trial not allowed)

- SBIR (R43/R44): [PAR-20-098](#)
- SBIR (R41/R42): [PAR-20-109](#)

Development of Highly Innovative Tools and Technology for Analysis of Single Cells (clinical trial not allowed)

- SBIR (R43/R44): [PA-20-047](#)
- STTR (R41/R42): [PA-20-025](#)

Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project

- SBIR (R43/R44): [PA-19-034](#)
- STTR (R41/R42): [PA-19-033](#)

SBIR and STTR applicants can apply for [Phase I and Phase II funding](#). SBIR applicants can also now opt to apply for [Direct-to-Phase II Funding](#). This award allows small businesses to submit Direct-to-Phase II SBIR applications if the small business has performed the Phase I stage-type research through other funding sources. The [SF424 SBIR/STTR Application Guide](#) with additional instructions for the SBIR Direct-to-Phase II application preparation and submission is also available.

New Contract Opportunity

NCATS is participating in a new SBIR contract opportunity under the National Institutes of Health and Centers for Disease Control and Prevention. The SBIR Contract Solicitation PHS-2021-1 is now available through both [beta.Sam.gov](#) and the [NIH SBIR/STTR funding site](#). Responses are due **October 26, 2020 at 5:00 pm EDT**. The following topics are included under NCATS:

- Topic 020 - Development of Remote Rare Disease Patient Care Environment through Immersive Virtual Reality

- Topic 021 - Platform for Rapidly Deployable Autonomous Laboratory

Point of Contact: [George Kennedy](#), 240-669-5170,
or [Tiffany Chadwick](#), 240-276-7293

Sam Taylor, President
North Carolina Biosciences Organization
P.O. Box 14354
Research Triangle Park, NC 27709
staylor@ncbioscience.net



You are receiving this announcement as part of your NCBIO membership. If you do not wish to receive announcements, please click the unsubscribe link provided below.

NCBIO | PO Box 14345 | Research Triangle Park, NC 27709